Project Description
Product description
The active substance in Almirid-Cripar is the hydrogenated ergot alkaloid a-dihydroergocryptine methane sulfonate, which has high affinity for dopamine receptors. alpha-Dihydroergocryptine methane sulfonate is a selective D2 receptor agonist and a partial D1 receptor agonist, and in vivo it has no activity on serotonergic or adrenergic receptors.
Indication
For the treatment of shaking palsy (idiopathic Parkinson’s disease) in patients without fluctuations in their clinical picture, either as monotherapy or in combination with levodopa (with or without a decarboxylase inhibitor).